CCL20 (Gene)

Organism:

Homo sapiens

Synonyms:C-C motif chemokine ligand 20, CCL20, CKb4, ENTREZ:6364, Exodus, HGNC:10619, LARC, MIM:601960, MIP-3-alpha, MIP-3a, MIP3A, NM_001130046, NM_004591, NP_001123518, NP_004582, SCYA20, ST38

Omim:OMIM:601960

Id:ENSG00000115009

Hgnc:HGNC:10619

Entrez:6364

Ensembl:ENSG00000115009

Description:C-C motif chemokine ligand 20

This antimicrobial gene belongs to the subfamily of small cytokine CC genes. Cytokines are a family of secreted proteins involved in immunoregulatory and inflammatory processes. The CC cytokines are proteins characterized by two adjacent cysteines. The protein encoded by this gene displays chemotactic activity for lymphocytes and can repress proliferation of myeloid progenitors. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Sep 2014]

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View CCL20's neighborhood in the knowledge graph.

Submit

Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with CCL20.

CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using CCL20.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for CCL20.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with CCL20.

Results found

Linked to

	Label	Description
	GSE240439 decitabine 1 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE135514 8 V 7 DASATINIB HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE172016 2 V 0 PACLITAXEL HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE192860 0 V 1 TRIFLUOPERAZINE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE217552 fisetin 3 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE234647 1 V 3 REGORAFENIB HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE144843 GSE144844 SMARCA2 SMARCA4 knockdown 5 v 3 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE233679 12 V 2 NICOTINAMIDE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE81796 0 V 2 ENZALUTAMIDE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE158552 BRD4 inhibition 2 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS

GSE240439 decitabine 1 v 2 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE135514 8 V 7 DASATINIB HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE172016 2 V 0 PACLITAXEL HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE192860 0 V 1 TRIFLUOPERAZINE HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE217552 fisetin 3 v 2 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE234647 1 V 3 REGORAFENIB HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE144843 GSE144844 SMARCA2 SMARCA4 knockdown 5 v 3 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE233679 12 V 2 NICOTINAMIDE HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE81796 0 V 2 ENZALUTAMIDE HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE158552 BRD4 inhibition 2 v 0 human dn

Gene Set (Entity type)

A Gene Set from LINCS

DISPLAY PER PAGE

CFDE Workbench

Consortium

Community

Resources

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

Consortium

Community

Resources

CFDE Workbench

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.